Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s stock price has increased by 1.09 compared to its previous closing price of 39.51. However, the company has seen a 0.76% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-29 that Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen’s FDA decision and olezarsen’s Phase 3 data, both with significant peak sales potential in underserved markets. Despite ongoing losses and commercial execution risks, Ionis’ validated platform and differentiated drugs offer compelling long-term growth opportunities.
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
Additionally, the 36-month beta value for IONS is 0.23. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for IONS is 155.28M and currently, short sellers hold a 9.16% ratio of that float. The average trading volume of IONS on July 02, 2025 was 1.74M shares.
IONS’s Market Performance
IONS stock saw an increase of 0.76% in the past week, with a monthly gain of 19.19% and a quarterly increase of 32.38%. The volatility ratio for the week is 2.31%, and the volatility levels for the last 30 days are 3.04% for Ionis Pharmaceuticals Inc (IONS). The simple moving average for the last 20 days is 7.43% for IONS stock, with a simple moving average of 14.69% for the last 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with Barclays repeating the rating for IONS by listing it as a “Overweight.” The predicted price for IONS in the upcoming period, according to Barclays is $57 based on the research report published on July 01, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IONS reach a price target of $45. The rating they have provided for IONS stocks is “Buy” according to the report published on April 07th, 2025.
Redburn Atlantic gave a rating of “Neutral” to IONS, setting the target price at $39 in the report published on March 31st of the current year.
IONS Trading at 16.92% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.69% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Hayden Michael R, who purchase 15,000 shares at the price of $31.86 back on May 01 ’25. After this action, Hayden Michael R now owns 50,219 shares of Ionis Pharmaceuticals Inc, valued at $477,900 using the latest closing price.
Birchler Brian, the EVP, Corp and Development Ops of Ionis Pharmaceuticals Inc, sale 680 shares at $28.37 during a trade that took place back on Apr 16 ’25, which means that Birchler Brian is holding 56,660 shares at $19,292 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.98 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.64. The total capital return value is set at -0.18. Equity return is now at value -118.53, with -16.41 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at 2.96. The interest coverage ratio of the stock is -5.26.
Currently, EBITDA for the company is -475.08 million with net debt to EBITDA at -2.97. When we switch over and look at the enterprise to sales, we see a ratio of 10.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.66.
Conclusion
In conclusion, Ionis Pharmaceuticals Inc (IONS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
